potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.fluvoxamineMonitor Closely (1)fluvoxamine and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.foscarnetMonitor Closely (1)formoterol and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fostemsavirMonitor Closely (1)formoterol and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. furosemideMonitor Closely (1)formoterol and furosemide both decrease serum potassium. Use Caution/Monitor.Minor (1)formoterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.galantamineMonitor Closely (1)galantamine increases and glycopyrrolate inhaled decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Minor (1)galantamine decreases effects of glycopyrrolate inhaled by pharmacodynamic antagonism. Minor/Significance Unknown.gemifloxacinMonitor Closely (1)gemifloxacin and formoterol both increase QTc interval. Use Caution/Monitor.gentamicinMonitor Closely (1)formoterol and gentamicin both decrease serum potassium. Use Caution/Monitor.gilteritinibMonitor Closely (1)gilteritinib and formoterol both increase QTc interval. Use Caution/Monitor.glasdegibSerious - Use Alternative (1)formoterol and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.glucagonSerious - Use Alternative (1)glucagon increases toxicity of glycopyrrolate inhaled by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .glucagon intranasalSerious - Use Alternative (1)glucagon intranasal increases toxicity of glycopyrrolate inhaled by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .glycopyrronium tosylate topicalMonitor Closely (1)glycopyrronium tosylate topical, glycopyrrolate inhaled. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.goserelinMonitor Closely (1)goserelin increases toxicity of formoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.green teaMinor (1)green tea increases effects of formoterol by pharmacodynamic synergism. Minor/Significance Unknown. Due to caffeine content. Combination may increase CNS stimulatory effects due to caffeine in green tea.haloperidolMonitor Closely (4)haloperidol increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. glycopyrrolate inhaled decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. haloperidol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. glycopyrrolate inhaled decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.Serious - Use Alternative (1)formoterol and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.henbaneMonitor Closely (1)glycopyrrolate inhaled and henbane both decrease cholinergic effects/transmission. Use Caution/Monitor.histrelinMonitor Closely (1)histrelin increases toxicity of formoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.homatropineMonitor Closely (1)glycopyrrolate inhaled and homatropine both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine AMonitor Closely (1)huperzine A increases and glycopyrrolate inhaled decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrochlorothiazideMonitor Closely (1)formoterol and hydrochlorothiazide both decrease serum potassium. Use Caution/Monitor.Minor (1)formoterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.hydromorphoneMonitor Closely (1)hydromorphone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydroxychloroquine sulfateSerious - Use Alternative (1)hydroxychloroquine sulfate and formoterol both increase QTc interval. Avoid or Use Alternate Drug.hydroxyzineMonitor Closely (1)hydroxyzine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.hyoscyamineMonitor Closely (1)glycopyrrolate inhaled and hyoscyamine both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayMonitor Closely (1)glycopyrrolate inhaled and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.ibuprofenMonitor Closely (1)ibuprofen increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.ibuprofen IVMonitor Closely (1)ibuprofen IV increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.ibutilideSerious - Use Alternative (1)formoterol and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.iloperidoneMonitor Closely (5)iloperidone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. glycopyrrolate inhaled decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. glycopyrrolate inhaled decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor. iloperidone increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. formoterol and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.imipramineMonitor Closely (3)glycopyrrolate inhaled and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. imipramine increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor. imipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)imipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug. imipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.indapamideMonitor Closely (1)formoterol and indapamide both decrease serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)formoterol and indapamide both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)formoterol, indapamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.indomethacinMonitor Closely (1)indomethacin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.inotuzumabSerious - Use Alternative (1)inotuzumab and formoterol both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.ipratropiumMonitor Closely (1)glycopyrrolate inhaled and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.isocarboxazidSerious - Use Alternative (1)isocarboxazid increases effects of formoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.isoproterenolMonitor Closely (3)formoterol and isoproterenol both decrease serum potassium. Use Caution/Monitor. formoterol and isoproterenol both decrease sedation. Use Caution/Monitor. formoterol and isoproterenol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.itraconazoleMonitor Closely (1)itraconazole and formoterol both increase QTc interval. Use Caution/Monitor.ivosidenibSerious - Use Alternative (1)ivosidenib and formoterol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.ketoconazoleSerious - Use Alternative (1)formoterol and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.ketoprofenMonitor Closely (1)ketoprofen increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.ketorolacMonitor Closely (1)ketorolac increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.ketorolac intranasalMonitor Closely (1)ketorolac intranasal increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .ketotifen, ophthalmicMonitor Closely (1)ketotifen, ophthalmic increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.labetalolMonitor Closely (2)labetalol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor. labetalol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.lapatinibMonitor Closely (1)formoterol and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lefamulinSerious - Use Alternative (1)lefamulin and formoterol both increase QTc interval. Avoid or Use Alternate Drug.lenvatinibMonitor Closely (1)formoterol and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.leuprolideMonitor Closely (1)leuprolide increases toxicity of formoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.levalbuterolMonitor Closely (3)formoterol and levalbuterol both decrease serum potassium. Use Caution/Monitor. formoterol and levalbuterol both decrease sedation. Use Caution/Monitor. formoterol and levalbuterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.levodopaMonitor Closely (1)glycopyrrolate inhaled, levodopa. Other (see comment). Use Caution/Monitor. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .levofloxacinMonitor Closely (1)formoterol and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levoketoconazoleSerious - Use Alternative (1)formoterol and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.levorphanolMonitor Closely (1)levorphanol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.linezolidSerious - Use Alternative (1)linezolid increases effects of formoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.lisdexamfetamineMonitor Closely (2)formoterol and lisdexamfetamine both decrease sedation. Use Caution/Monitor. formoterol and lisdexamfetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.lofepramineMonitor Closely (2)glycopyrrolate inhaled and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor. lofepramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)lofepramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug. lofepramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.Minor (1)lofepramine increases levels of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.lofexidineMonitor Closely (1)lofexidine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.loprazolamMonitor Closely (1)loprazolam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lorazepamMonitor Closely (1)lorazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lormetazepamMonitor Closely (1)lormetazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lornoxicamMonitor Closely (1)lornoxicam increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.loxapineMonitor Closely (4)loxapine increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. glycopyrrolate inhaled decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor. loxapine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. glycopyrrolate inhaled decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.loxapine inhaledMonitor Closely (4)glycopyrrolate inhaled decreases levels of loxapine inhaled by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. glycopyrrolate inhaled decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. loxapine inhaled increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. loxapine inhaled increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lumefantrineSerious - Use Alternative (1)formoterol and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.macimorelinSerious - Use Alternative (1)macimorelin and formoterol both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.maprotilineMonitor Closely (3)glycopyrrolate inhaled and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor. maprotiline increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor. maprotiline increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)maprotiline, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. maprotiline and formoterol both increase QTc interval. Avoid or Use Alternate Drug.marijuanaMonitor Closely (1)marijuana increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.meclizineMonitor Closely (1)glycopyrrolate inhaled and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.meclofenamateMonitor Closely (1)meclofenamate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.mefenamic acidMonitor Closely (1)mefenamic acid increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.melatoninMonitor Closely (1)melatonin increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.meloxicamMonitor Closely (1)meloxicam increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.meperidineMonitor Closely (1)meperidine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.meprobamateMonitor Closely (1)meprobamate increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaproterenolMonitor Closely (3)formoterol and metaproterenol both decrease serum potassium. Use Caution/Monitor. formoterol and metaproterenol both decrease sedation. Use Caution/Monitor. formoterol and metaproterenol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.methadoneMonitor Closely (2)formoterol and methadone both increase QTc interval. Modify Therapy/Monitor Closely. methadone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methamphetamineMonitor Closely (2)formoterol and methamphetamine both decrease sedation. Use Caution/Monitor. formoterol and methamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.methscopolamineMonitor Closely (1)glycopyrrolate inhaled and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.methyclothiazideMonitor Closely (1)formoterol and methyclothiazide both decrease serum potassium.